MedTrace Logo

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

NCT02661971 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2022-07-11

No results posted yet for this study

Summary

Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of ramucirumab in combination with FLOT in the perioperative treatment of resectable adenocarcinoma of the stomach or GEJ.

Conditions

Interventions

DRUG

Docetaxel

Docetaxel 50 mg/m², d1

DRUG

Oxaliplatin

Oxaliplatin 85 mg/m², d1

DRUG

Calciumfolinat

Leucovorin 200 mg/m², d1

DRUG

5-Fluorouracil

5-FU 2600 mg/m², d1

BIOLOGICAL

Ramucirumab

Ramucirumab 8mg/kg, d1

Sponsors & Collaborators

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, Prof. Dr. · Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2021-12-31
Completion
2022-06-20

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661971 on ClinicalTrials.gov